These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 19878631)
1. observational studies: propensity score analysis of non-randomized data. Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Di Renzo V Int MS J; 2009 Sep; 16(3):90-7. PubMed ID: 19878631 [TBL] [Abstract][Full Text] [Related]
2. Optic neuritis: a review. Shams PN; Plant GT Int MS J; 2009 Sep; 16(3):82-9. PubMed ID: 19878630 [TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab. Bates D Int MS J; 2009 Sep; 16(3):75-6. PubMed ID: 19899240 [TBL] [Abstract][Full Text] [Related]
4. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Vollmer TL; Wynn DR; Alam MS; Valdes J Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis. Boggild M; Ford H Clin Evid; 2002 Jun; (7):1195-207. PubMed ID: 12230737 [No Abstract] [Full Text] [Related]
7. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044 [TBL] [Abstract][Full Text] [Related]
9. Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique. Conway DS; Miller DM; O'Brien RG; Cohen JA Mult Scler; 2012 Nov; 18(11):1617-24. PubMed ID: 22653659 [TBL] [Abstract][Full Text] [Related]
10. No shortcuts to outcome in MS clinical trials? Koch-Henriksen N Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696 [No Abstract] [Full Text] [Related]
11. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [TBL] [Abstract][Full Text] [Related]
12. Lessons from linomide: a failed trial, but not a failure. Schwid SR; Trotter JL Neurology; 2000 May; 54(9):1716-7. PubMed ID: 10802772 [No Abstract] [Full Text] [Related]
13. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802 [TBL] [Abstract][Full Text] [Related]
14. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Tan IL; Lycklama à Nijeholt GJ; Polman CH; Adèr HJ; Barkhof F Mult Scler; 2000 Apr; 6(2):99-104. PubMed ID: 10773855 [TBL] [Abstract][Full Text] [Related]
15. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Hersh CM; Cohen JA Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071 [TBL] [Abstract][Full Text] [Related]
17. [Results of a multicenter study of Rebif-22 mcg administration in Russia]. Zavalishin IA; Gusev EI; Iakhno NN; Skoromets AA; Boĭko AN; Demina TL; Burlutskiĭ A P ; Beĭn BN; Sholomov II; Pereserdova AV; Stoĭda NI; Zakharova MN; Adarcheva LS; Niiazbekova AS; Askarova LSh; Oleĭnikov VG; Rebrova OIu; Shmidt TE; Davydovskaia MV; Totolian NA; Beskhmel'nitsina IA; Bragina OV; Ponomareva GL; Durseneva OM; Voronchikhina SA; Volkova LI; Turova EL; Streknev AG Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):73-8. PubMed ID: 12938639 [TBL] [Abstract][Full Text] [Related]
18. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Lobo FS; Wagner S; Gross CR; Schommer JC Res Social Adm Pharm; 2006 Mar; 2(1):143-51. PubMed ID: 17138506 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of progressive forms of multiple sclerosis]. Edan G Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1008-13. PubMed ID: 11787331 [TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A; Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]